The Anti-Diabetes Drugs market in Switzerland has been experiencing steady growth in recent years.
Customer preferences: Swiss consumers are increasingly health-conscious and are actively seeking out products to manage their health. This has led to an increased demand for anti-diabetes drugs as the prevalence of diabetes in Switzerland continues to rise. Consumers are also becoming more aware of the potential complications associated with diabetes, such as cardiovascular disease and kidney failure, and are seeking out drugs that can effectively manage their condition.
Trends in the market: One trend in the Swiss Anti-Diabetes Drugs market is the increasing use of combination therapies. Combination therapies involve the use of multiple drugs to manage diabetes, and are becoming more popular as they can be more effective than single drug therapies. Another trend in the market is the increasing use of newer drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors. These drugs have been shown to be effective in managing diabetes and have fewer side effects compared to older drugs.
Local special circumstances: Switzerland has a high rate of diabetes, with approximately 5% of the population affected by the disease. This has led to a high demand for anti-diabetes drugs in the country. The Swiss healthcare system is also well-developed, with a strong emphasis on preventative care. This has led to increased access to anti-diabetes drugs for Swiss consumers, as the government provides subsidies for these drugs.
Underlying macroeconomic factors: The Swiss economy has been growing steadily in recent years, with a strong emphasis on innovation and technology. This has led to increased investment in the healthcare sector, including the development of new anti-diabetes drugs. The aging population in Switzerland is also a factor driving growth in the Anti-Diabetes Drugs market, as older individuals are more likely to develop diabetes and require medication to manage their condition.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
